marketcaparena

XTL Biopharmaceuticals Ltd.

XTLB

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

xtlbio.com ↗

Employees
10
Business address
NEW YORK, NY
Listed
Nasdaq · XTLB

Price

Share price

Daily closing price. The header shows the latest close, the market cap at that close and the change over the selected range. Hover or tap the chart to read any day.
$2.23
−$2.45 (−52.35%)past year
Market cap
$5M
At close
Sep 28, 2026

Share price vs index

XTL Biopharmaceuticals's share price and the index, each as its percentage change since the first day of the selected range. The shading shows the gap: green while XTL Biopharmaceuticals is ahead, orange while it is behind. The values at the end are each one's change over the range.

Income statement

Revenue, gross profit and net income

FY25
Full year
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Income statement

FY24
Full year
How revenue becomes net income in the chosen year or quarter. Solid bars are totals; hatched bars are the costs taken off between them.
TotalAddedSubtracted

Cash flow

Operating and free cash flow

FY25
Full year
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Cash flow statement

FY25
Full year
The reported movements behind the change in cash in the chosen year or quarter. Solid bars are totals; hatched bars are what was added or taken off between them.
TotalAddedSubtracted

Capital allocation

FY25
Full year
Operating cash flow above zero; what it was spent on below: capital expenditure, dividends and buybacks.

Stock-based compensation

FY25
Full year
Stock-based compensation reported in the cash flow statement each period. The line is that amount as a percentage of the same period's revenue.
Stock-based compensation% of revenue

Balance sheet

Assets, liabilities and equity

Q4 25
Full year
Quarter
The balance sheet at the end of the chosen year or quarter. What the company owns on the left, against what it owes and what belongs to shareholders on the right. Both columns add up to total assets.

War chest

Q4 25
Full year
Quarter
Cash and short-term investments held at each quarter end. The figure at the top of each column is the total.